Studies have shown that active fund managers routinely underperform the S&P500 index*​

Rapport Therapeutics, Inc. (NASDAQ: RAPP)

RAPP Stock Predictions and Ratings

WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-17.70%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
32.30%

RAPP Stock Analysis

RAPP PE Ratio:

RAPP PEG Ratio: Not Available

RAPP Forward EPS Growth (12 month): 0.00%

RAPP PS Ratio: 67.5

RAPP PSG Ratio: Not Available

RAPP Forward Revenue Growth (12 month): 0.00%

RAPP Articles

No data was found